Injectable Cytotoxic Drugs Market Report 2025

The injectable cytotoxic drugs market size has grown strongly in recent years. It will grow from $18.16 billion in 2024 to $19.41 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period was driven by greater adoption of combination chemotherapy treatments, increased healthcare expenditure, a growing number of cancer specialty clinics and treatment centers, more approvals of generic injectable cytotoxic drugs, and heightened awareness of early cancer detection.

The injectable cytotoxic drugs market size is expected to see strong growth in the next few years. It will grow to $25.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The projected growth during the forecast period is driven by the increasing use of biosimilar cytotoxic drugs, greater emphasis on outpatient and home-based chemotherapy, an expanding pipeline of injectable oncology drugs, rising cancer incidence, and growing demand for affordable cancer treatments. Key trends expected in this period include advancements in injectable drug delivery technologies, innovative formulation methods to minimize toxicity, progress in antibody-drug conjugate development, the integration of AI in oncology drug discovery, and increased collaboration among pharmaceutical companies.

The rising incidence of rheumatoid arthritis is expected to drive the growth of the injectable cytotoxic drugs market in the coming years. Rheumatoid arthritis is a chronic autoimmune disorder marked by ongoing joint inflammation, pain, and eventual joint damage. The increase in rheumatoid arthritis cases is mainly due to an aging population, as advancing age raises the risk of genetic mutations and immune system dysfunction that contribute to the condition. Injectable cytotoxic drugs treat rheumatoid arthritis by targeting rapidly dividing cells and suppressing overactive immune responses, thereby slowing disease progression and alleviating symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, an independent statutory agency, reported that rheumatoid arthritis caused 1,322 deaths, equating to 5.1 deaths per 100,000 people, and accounted for 0.7% of all deaths in 2022. It contributed to 2% of the overall disease burden and represented 16% of the total burden from all musculoskeletal conditions in 2023. Therefore, the growing incidence of rheumatoid arthritis is fueling the expansion of the injectable cytotoxic drugs market.

Key players in the injectable cytotoxic drugs market are concentrating on securing regulatory approvals to broaden their product lines and speed up market entry. Regulatory approvals are formal authorizations granted by health authorities confirming that a drug meets required safety, efficacy, and quality standards before marketing and prescription. For instance, in March 2024, Astellas Pharma Inc., a pharmaceutical company based in Japan, received approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) for VYLOY (zolbetuximab) to treat CLDN18.2-positive, unresectable, advanced, or recurrent gastric cancer. This approval was supported by Phase III clinical trials (SPOTLIGHT and GLOW) showing that VYLOY combined with chemotherapy significantly improves progression-free and overall survival. Patient eligibility is determined using a companion diagnostic test that detects CLDN18.2 expression in tumor cells. This therapy addresses a critical unmet need in gastric cancer, which is often diagnosed late and linked to poor prognosis worldwide.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer aims to strengthen its leadership in oncology by leveraging Seagen’s leading Antibody-Drug Conjugate (ADC) technology, an advanced form of targeted cytotoxic therapy, to expand its treatment portfolio and speed up the development of next-generation cancer therapies. Seagen Inc. is a US-based company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for cancer treatment, including injectable cytotoxic drugs.

Major players in the injectable cytotoxic drugs market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Sanofi S.A., Bristol‑Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Baxter International Inc., Fresenius Kabi AG, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Jazz Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Zydus Lifesciences Ltd., Zydus Lifesciences Ltd., and NATCO Pharma Ltd.

North America was the largest region in the injectable cytotoxic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injectable cytotoxic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the injectable cytotoxic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The injectable cytotoxic drugs market consists of sales of products, including topoisomerase inhibitors, taxanes, mitotic inhibitors, radiopharmaceutical cytotoxics, and targeted cytotoxic conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The injectable cytotoxic drugs market research report is one of a series of new reports that provides injectable cytotoxic drugs market statistics, including injectable cytotoxic drugs industry global market size, regional shares, competitors with an injectable cytotoxic drugs market share, detailed injectable cytotoxic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the injectable cytotoxic drugs industry. This injectable cytotoxic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Injectable cytotoxic drugs are medications delivered by injection that target and destroy rapidly dividing cancer cells. These drugs are primarily used in chemotherapy and function by disrupting the cell division process to halt tumor growth.

The primary types of injectable cytotoxic drugs include alkylating agents, antimetabolites, plant alkaloids, antitumor antibiotics, platinum-based compounds, cytotoxic antibiotics, and others. Alkylating agents function by binding alkyl groups to DNA, causing damage that inhibits cancer cell replication. These drugs can be administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes and are supplied via hospital pharmacies, retail pharmacies, online pharmacies, and specialty drug stores. They are used to treat a variety of cancers, including breast, lung, prostate, colorectal, ovarian cancers, lymphoma, and leukemia. Key end users include hospitals, oncology clinics, ambulatory surgical centers, and research and academic institutions.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.